Furthermore, METTL3 has been implicated in bladder cancer by promoting resistance to CD8+ T cell cytotoxic effects through the upregulation of programmed death ligand 1 (PD-L1) expression, underscoring the importance of m6A methylation in tumor immunity modulation [54]. The gene discussed is METTL3; the disease is urinary bladder carcinoma.